• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

From Ituri to Geneva, in the search for new medicines for river blindness

Home > Stories

From Ituri to Geneva, in the search for new medicines for river blindness

2 Sep 2024

Lire en Français

Congolese researcher and physician Dr Jack Zawadi Tsulokpa is a 2024 fellow of the WHO-TDR Clinical Research Leadership program. He joined DNDi’s filarial team in April 2024, for a year, to contribute to our research work on river blindness, bringing his vast field experience managing clinical trials in the DRC – including in areas hit by armed conflicts.

Dr Zawadi is affiliated with the Tropical Diseases Research Centre (Centre de Recherche en Maladies Tropicales, or CRMT) in Rethy, in the Ituri province in North-Eastern Democratic Republic of the Congo (DRC), where he was investigator of a Phase III trial to test the efficacy and safety of moxidectin against river blindness.

Dr Zawadi, what do you hope to get out of your TDR fellowship?

My work at the CRMT has given me a taste for research. There are not enough researchers in our region, not enough epidemiologists to alert and advise authorities, even though the needs are immense. I want to identify the health problems in our communities and conduct studies that will provide the epidemiological data needed to inform the authorities so they can act.

‘Because of the tense geopolitical context in my home region, out of fear for their safety, few researchers are able to look into the health problems affecting the populations, who find themselves neglected.’

Dr Jack Zawadi

An ongoing epidemic of plague has been affecting the health districts of Rethy, Linga, Jiba, and Logo since 2020, for example; but the persistent insecurity in the region and the lack of data prevent effective interventions.

This fellowship also represents a crucial opportunity for the tropical diseases research centre I work for. To ensure the sustainability of its activities, the CRMT needs to have experienced and skilled researchers – especially in the procedures required to conduct clinical studies.

That is why I intend to build on my year at DNDi to refine my knowledge of clinical research project management. I hope that this experience will help me to enter the world of research more effectively, which also means improving my command of English and… computer tools!

What is your role in the DNDi team?

I am working on a Phase II clinical trial testing the safety and efficacy of a molecule called emodepside against river blindness. My contribution includes – among many other things – reviewing the protocol, the investigator’s manual and the procedures, to adapt them to the reality of the field and to make it easier for the research teams at the trial sites to understand them.

From a personal perspective, by working alongside DNDi researchers, I will be learning a lot about the management of a clinical trial, including its design, its protocol, the drafting of all necessary documentation, the requirements of regulatory authorities and ethics committees, and partnership contracts.

I also want to master the role and responsibilities of a principal investigator, who acts as the focal point between the sponsor and the authorities. I’ll be learning by doing, and I’m delighted to share this journey together with DNDi.

Onchocerca volvulus (the river blindness parasite)
Onchocerca volvulus
(the river blindness parasite)

You talk of the ‘reality of the field’ – can you describe the reality of conducting a clinical trial in a conflict zone?

Before joining the CRMT, I was working as a physician at the Libi referral health centre, in Ituri province. In mid-2019, armed clashes between the rebels and the regular army forced me and my family to leave. During this period, I joined the Ebola response team as a supervisor. I returned to Libi in April 2020, in the context of constant displacements of people fleeing the atrocities of armed groups.

In February 2021, I was recruited by the CMRT as an investigator for a clinical study on river blindness. A week after my departure from Libi, the referral health centre where I was working was looted by armed men who stole the equipment in the operating theatre, the stock of medicines and the mattresses on the patients’ beds. The centre remained closed for almost 18 months.

The CRMT research team in Rethy, Ituri province

The CMRT clinical study that I joined was a Phase IIIb trial that was testing the safety and efficacy of one or two annual doses of moxidectin, compared with ivermectin, in the rural health zone of Logo, in the Mahagi territory, near Uganda. The team was fantastic. Our activities were sometimes affected by the raids of armed groups in the villages where the study participants lived, which were provoking population displacements, and disrupting patient recruitment and follow-up activities.

These armed incursions were also a threat for us, the CMRT staff, and our families. My second child was born in the General Reference Hospital in Rethy during a period of regular clashes between armed groups and the loyalist army, and sometimes between rival factions; on the day he was born, I was returning from the field with my team, and we were ambushed and even shot at. Fortunately, we made it back to the CRMT office unharmed.

These are the realities that must be considered when conducting trials in some of endemic regions of the DRC in recent years.

What are your plans after this fellowship?

In the DRC region where I work, all neglected tropical diseases have a strong social and economic impact. Some people affected by NTDs become socially isolated and don’t have access to healthcare. The topography of the region, with its forests and fast-flowing rivers, is well-suited to the spread of river blindness in particular – but also of other diseases that need to be more investigated.

After this fellowship, my plan is to continue working with the CRMT, particularly to carry out prevalence studies of river blindness and other diseases that are neglected because of access difficulties and recurring insecurity problems. I hope that the strong links forged with DNDi will help to advance the work of CRMT’s researchers, and consequently support vulnerable populations who do not have access to the care they need.

Developing new molecules against neglected diseases by conducting clinical trials in the region can play a vital role in these efforts. That’s why this fellowship at DNDi is so important.

Thank you Jack!

Filaria: river blindness Africa Democratic Republic of Congo Switzerland

Read, watch, share

Loading...
News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License